invoX Pharma, a UK-based wholly-owned subsidiary of Sino Biopharmaceutical, with an advancing pipeline of innovative products, has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.   pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. The company’s proprietary RALA platform can deliver anionic […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!